ArticleKorean circulation journal2021
Cost-Effectiveness Analysis of Hypertension Screening in the Korea National Health Screening Program.
Article in Korean circulation journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Economic Evaluation of Pharmacopuncture for Adhesive Capsulitis Alongside a Pilot Pragmatic Randomized Controlled Trial Comparing Pharmacopuncture and Physical Therapy.Healthcare (Basel, Switzerland) · 2026Article
- Cost-effectiveness of chronic obstructive pulmonary disease population screening in China: based on individual data from WHO Collaborating Centre-initiated 'Enjoying Breathing Program'.BMC public health · 2025Article
- Article
- Impact of COVID-19 on national health screening participation and chronic disease detection: evidence from South Korea's NHIS database.Frontiers in public health · 2025Article
- Effect of the oral examinations in the national health screening program on preventive oral health care and treatments: a 19-year follow-up study.BMC oral health · 2024Article
- Cost-effectiveness of strengthening blood pressure classification in South Korea: comparing the 2017 ACC/AHA and KSH guidelines.Clinical hypertension · 2024Article
- Cost-effectiveness of population-based screening for chronic obstructive pulmonary disease in China: a simulation modeling study.The Lancet regional health. Western Pacific · 2024Article
- Increased risk of ischemic stroke associated with elevated gamma-glutamyl transferase level in adult cancer survivors: a population-based cohort study.Scientific reports · 2023Article
- Epidemiology of PAH in Korea: An Analysis of the National Health Insurance Data, 2002-2018.Korean circulation journal · 2023Article
- Current Status of the National Health Screening Programs in South Korea.Korean journal of family medicine · 2022Article
- Cost-effectiveness analysis of intensive blood pressure control in Korea.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Optimal Strategy of Hypertension Screening in a Nationwide Health Examination: Early and Periodic Blood Pressure Measurement.Korean circulation journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesTo evaluate the cost-effectiveness of routine hypertension (HTN) screening as a part of the national health-screening program.
methodsTwo aspects of cost-effectiveness were examined using the national general health-screening program. First, the cost of case-finding was computed for 5-year interval age groups. Second, the cost per quality adjusted life years (QALYs) gained were estimated for 12 different scenarios varying examination starting age, pattern and interval compared with no screening.
resultsThe cost of finding one new HTN case was low as 26,284 Korean won (KRW) (approximately [approx.] United States Dollar 21) for 70-79 years old to as high as 70,552 KRW for 40-44 years old. Compared with no screening, the costs per QALYs of the following screening strategies were below the incremental cost-effectiveness ratio threshold (approx. KRW 30.5 million): first screening examination with the second confirmatory examination in adults aged ≥40 years every 3 years (KRW 10.2 million), every 2 years (KRW 13.2 million), or annually (KRW 19.9 million). One-way sensitivity analyses suggest that the results were mostly influenced by the sensitivity of the first screening examination, followed by the examination rate of the second confirmatory examination.
conclusionsHTN screening as a part of routine national health screening program was cost-effective for adults aged 40 years or older. The most cost-effective HTN screening strategy was the first screening examination with the second confirmatory examination in aged 40 years or older every 3 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.